Clinical Advances in Hematology and Oncology : Impact Factor & More
eISSN: 1543-0790pISSN: 1543-0790
Share this on:
Key Metrics
CiteScore 
1.2
SJR
Q4Oncology
SNIP
0.67
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Clinical Advances in Hematology and Oncology Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | MILLENNIUM MEDICAL PUBLISHING, INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2003 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers in Clinical Advances in Hematology and Oncology
The diagnosis and treatment of red cell membrane disorders: algorithm for the general hematologist.
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
Management of low-grade serous carcinoma of the ovary.
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
Access to novel cancer drugs in low- and middle-income countries.
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
Translating FRESCO clinical trial evidence into practice: fruquintinib as post-standard third-line therapy followed by trifluridine/tipiracil in a patient with mCRC without targetable mutations.
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
What is the role of asciminib in chronic myeloid leukemia?
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
Ravulizumab-danicopan combination therapy in PNH management.
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
The diagnosis and treatment of red cell membrane disorders: algorithm for the general hematologist.
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
Management of low-grade serous carcinoma of the ovary.
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
Access to novel cancer drugs in low- and middle-income countries.
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
Translating FRESCO clinical trial evidence into practice: fruquintinib as post-standard third-line therapy followed by trifluridine/tipiracil in a patient with mCRC without targetable mutations.
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
What is the role of asciminib in chronic myeloid leukemia?
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
Ravulizumab-danicopan combination therapy in PNH management.
- 1 Dec 2025
- Clinical advances in hematology & oncology : H&O
FAQs on Clinical Advances in Hematology and Oncology
How long has Clinical Advances in Hematology and Oncology been actively publishing? 
What is the publishing frequency of Clinical Advances in Hematology and Oncology?
How many articles did Clinical Advances in Hematology and Oncology publish last year?
What is the eISSN & pISSN for Clinical Advances in Hematology and Oncology?
What is Citescore for Clinical Advances in Hematology and Oncology?
What is SNIP score for Clinical Advances in Hematology and Oncology?
What is the SJR for Clinical Advances in Hematology and Oncology?
Who is the publisher of Clinical Advances in Hematology and Oncology?
